SHANKUS PHARMA PRIVATE LTD

Overview

SHANKUS PHARMA PRIVATE LTD is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering AGOMELATINE IH; DULOXETINE HYDROCHLORIDE EP/BP; DULOXETINE HYDROCHLORIDE USP; LERCANIDIPINE HYDROCHLORIDE IH; LINAGLIPTIN IH; MOXIFLOXACIN HYDROCHLORIDE EP BP.

API / Drug Master Files

SHANKUS PHARMA PRIVATE LTD holds 7 active (7 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• DULOXETINE HYDROCHLORIDE USPActive2026-01-07
• DULOXETINE HYDROCHLORIDE EP/BPActive2025-12-09
• AGOMELATINE IHActive2025-11-07
• LERCANIDIPINE HYDROCHLORIDE IHActive2025-09-29
• LINAGLIPTIN IHActive2025-09-29
• MOXIFLOXACIN HYDROCHLORIDE USPActive2025-09-26
• MOXIFLOXACIN HYDROCHLORIDE EP BPActive2025-09-26

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SHANKUS PHARMA PRIVATE LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.